Brief: Eloxx Pharmaceuticals Reports Q4 Loss Per Share $0.29
05/03/2020 22:23
March 5 (Reuters) - Eloxx Pharmaceuticals Inc ELOX.O :
* ELOXX PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR
2019
FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE
* Q4 LOSS PER SHARE $0.29
* Q4 EARNINGS PER SHARE ESTIMATE $-0.33 -- REFINITIV IBES
DATA
* TOPLINE DATA FROM PHASE 2 CYSTIC FIBROSIS CLINICAL TRIALS
FOR
ELX-02 IN H1 2020
Source text for Eikon: ID:nGNX5SlRw3
Further company coverage: ELOX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eloxx Pharmaceuticals
See all newsNASDAQ RESUMED AT 02:24 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:19 PM
Brief: Eloxx Pharmaceuticals Provides ELX-02 And ZKN-013 Program Updates
Brief: Eloxx Pharmaceuticals Confirms That Alport Syndrome Patients Treated With Elx-02 In Phase 2 Study Had Improvement
Brief: Eloxx Pharmaceuticals Inc Reports Results In All Patients Treated With Elx-02 In Phase 2 Clinical Study For Alport Syndrome